• A recent audit reveals that 64% of clinical trials supporting FDA approval for top-selling medicines in 2021 are eligible for independent data access, marking progress in transparency.
• Data sharing rates are higher among pharmaceutical companies utilizing independent platforms, suggesting third-party management enhances transparency and reduces potential conflicts of interest.
• Despite progress, 32% of trials were ineligible for data sharing, and 4% required a full research proposal, highlighting ongoing challenges in data accessibility.
• Researchers emphasize the need for pharmaceutical companies to improve data accessibility, especially for trials pivotal to product approval, to foster trust and benefit researchers and patients.